Classes
DEA Class; Rx
Common Brand Names; Briviact
- SV2A Ligands
Description
2-pyrrolidine derivative and levetiracetam analog
Used for partial onset seizures in patients 1 month and older
Increased risk of suicidal ideation and behavior
Indications
Indicated for the treatment of partial seizures.
Contraindications
Hypersensitivity; bronchospasms and angioedema have occurred
Adverse Effects
Somnolence and sedation (16%)
Dizziness (12%)
Fatigue (9%)
Nausea and vomiting (5%)
Cerebellar coordination and balance disturbances (3%)
Irritability (3%)
Constipation (2%)
Warnings
May cause psychiatric adverse reactions, including nonpsychotic and psychotic symptoms; advise patients and caregivers/families to be alert for these behavioral changes and report them to their physician immediately
Hypersensitivity reactions reported, including bronchospasm and angioedema; if a patient develops hypersensitivity reactions after treatment, the drug should be discontinued
If discontinued, withdraw drug gradually because of the risk of increased seizure frequency and status epilepticus; if withdrawal is needed because of a serious adverse event, consider rapid discontinuation
Pregnancy and Lactation
No adequate and well-controlled studies in pregnant women
Unknown if distributed in human breast milk
Maximum Dosage
200 mg/day PO or IV.
200 mg/day PO or IV.
16 to 17 years: 200 mg/day PO or IV.
13 to 15 years weighing 50 kg or more: 200 mg/day PO or IV.
13 to 15 years weighing 20 to 49 kg: 4 mg/kg/day PO or IV.
weighing 50 kg or more: 200 mg/day PO or IV.
weighing 20 to 49 kg: 4 mg/kg/day PO or IV.
weighing 11 to 19 kg: 5 mg/kg/day PO or IV.
weighing less than 11 kg: 6 mg/kg/day PO or IV.
weighing 11 to 19 kg: 5 mg/kg/day PO or IV.
weighing less than 11 kg: 6 mg/kg/day PO or IV.
Safety and efficacy have not been established.
How supplied
Brivaracetam
tablet: Schedule V
- 10mg
- 25mg
- 50mg
- 75mg
- 100mg
oral solution: Schedule V
- 10mg/mL
injection, solution: Schedule V
- 50mg/5mL single-dose vial
